Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PHILLIP J GOLDSTEIN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1346406147
CMS profile
715307
Location
GREENVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$3,156.46

91 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PHILLIP J GOLDSTEIN

NPI 1346406147 · CMS profile ID 715307

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

GREENVILLE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346406147?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PHILLIP J GOLDSTEIN, NPI 1346406147, CMS profile ID 715307. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346406147?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PHILLIP J GOLDSTEIN, NPI 1346406147, CMS profile ID 715307. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346406147?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PHILLIP J GOLDSTEIN, NPI 1346406147, CMS profile ID 715307, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1346406147?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

91 matching records · $3,156.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 91 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–91 of 91.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
QOL Medical, LLC $400.0006/03/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731212571 CMS
QOL Medical, LLC $17.7006/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731212495 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.1805/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737532051 CMS
AbbVie Inc. $8.9505/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827053 CMS
QOL Medical, LLC $16.6005/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731212499 CMS
AbbVie Inc. $20.0805/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827049 CMS
Romark Laboratories, LC $16.6504/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749989751 CMS
QOL Medical, LLC $9.5904/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731212507 CMS
Allergan, Inc. $14.2003/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723439131 CMS
AbbVie Inc. $13.2403/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827045 CMS
AbbVie Inc. $14.8203/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827041 CMS
Merck Sharp & Dohme Corporation $11.7203/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747713009 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.2403/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737532049 CMS
Janssen Biotech, Inc. $11.0503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719354625 CMS
AbbVie Inc. $11.2603/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827037 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.2602/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737532047 CMS
AbbVie Inc. $16.7402/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827033 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.0802/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737532043 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.4902/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737532045 CMS
AbbVie Inc. $51.1002/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827029 CMS
IRONWOOD PHARMACEUTICALS, INC $11.4802/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749790377 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $10.8102/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737532041 CMS
AbbVie Inc. $12.5702/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827025 CMS
QOL Medical, LLC $6.9002/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 731212547 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.3001/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747174765 CMS
AbbVie Inc. $19.3401/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827021 CMS
AbbVie Inc. $10.5901/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827017 CMS
Gilead Sciences, Inc. $20.1301/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747970393 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.6001/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737532039 CMS
AbbVie Inc. $20.1501/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827013 CMS
Allergan, Inc. $13.5001/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723439129 CMS
UCB, Inc. $12.6501/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 746061919 CMS
Adare Pharmaceuticals, Inc. $219.5201/12/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444397 CMS
Adare Pharmaceuticals, Inc. $219.5201/12/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444399 CMS
Adare Pharmaceuticals, Inc. $170.4901/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444325 CMS
Adare Pharmaceuticals, Inc. $683.3901/11/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444393 CMS
Adare Pharmaceuticals, Inc. $152.0201/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750444323 CMS
Merck Sharp & Dohme Corporation $11.7901/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747644381 CMS
AbbVie Inc. $17.4701/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827009 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.9701/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747174759 CMS
AbbVie Inc. $12.9701/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721827005 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,086.76 146
PY2020 $3,156.46 91
PY2021 $2,556.22 147
PY2022 $2,975.59 181
PY2023 $2,435.84 150
PY2024 $2,951.30 159
PY2025 $3,303.81 170

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $168,298.94 72
PY2024 Principal investigator $202,773.78 41
PY2023 Principal investigator $223,446.84 48
PY2022 Principal investigator $60,191.58 23
PY2021 Recipient $4,599.00 1
PY2021 Principal investigator $137,081.86 30
PY2020 Recipient $693.52 4
PY2020 Principal investigator $247,920.22 46
PY2019 Recipient $2,453.31 2
PY2019 Principal investigator $339,148.14 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,738.00 12/11/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure No dispute reported 06/30/2026 1244051831
Principal investigator 1 ABBVIE INC. $2,824.90 12/04/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202527334
Principal investigator 1 Eli Lilly and Company $4,750.00 12/03/2025 Non-covered Recipient Entity
RESEARCH ALLIANCE INC
MIRIKIZUMAB LY3074828 PRO UC CD - OMVOH - ULCERATIVE COLITIS No dispute reported 06/30/2026 1187890380
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780102
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780104
Principal investigator 1 Boehringer Ingelheim International GmbH $1.00 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780106
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780150
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780152
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 11/19/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780154
Principal investigator 1 ABBVIE INC. $3,375.00 11/12/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202523817
Principal investigator 1 ABBVIE INC. $3,402.10 11/04/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202520197
Principal investigator 1 ABBVIE INC. $3,073.20 10/09/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202514235
Principal investigator 1 ABBVIE INC. $8,700.90 10/01/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202512922
Principal investigator 1 ABBVIE INC. $3,286.40 09/03/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202507303
Principal investigator 1 ABBVIE INC. $1,978.99 08/26/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) No dispute reported 06/30/2026 1202505899
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780094
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780096
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780098
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780100
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780142
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780144
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780146
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 08/26/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780148
Principal investigator 1 Genentech, Inc. $2,471.00 08/26/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211583960
Principal investigator 1 ABBVIE INC. $2,772.90 08/05/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202501422
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780090
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780092
Principal investigator 1 ABBVIE INC. $530.40 07/10/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202497912
Principal investigator 1 ABBVIE INC. $1,589.90 07/02/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202495245
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,403.00 07/02/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282046
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,871.90 07/02/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282054
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,362.00 07/02/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282132
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,668.00 07/02/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223282138
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780140
Principal investigator 1 Boehringer Ingelheim International GmbH $4,500.00 06/23/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780084
Principal investigator 1 Boehringer Ingelheim International GmbH $1,534.00 06/23/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780086
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 06/23/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780088
Principal investigator 1 Genentech, Inc. $8,303.00 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211583951
Principal investigator 1 Genentech, Inc. $9,716.10 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
vixarelimab ulcerative colitis study No dispute reported 06/30/2026 1211583955
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,120.00 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281670
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,280.00 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281672
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $574.00 06/20/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1223281674
Principal investigator 1 ABBVIE INC. $7,524.40 06/03/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202488869
Principal investigator 1 ABBVIE INC. $8,895.90 05/14/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202484861
Principal investigator 1 ABBVIE INC. $8,700.90 04/23/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202478606
Principal investigator 1 ABBVIE INC. $11,037.00 04/03/2025 Non-covered Recipient Entity
CAROLINA RESEARCH
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202471464
Principal investigator 1 ABBVIE INC. $3,374.80 04/03/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202471467
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.83 03/10/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
Proof of Clinical Principal in Crohn's Disease No dispute reported 06/30/2026 1220998971
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 03/06/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780124
Principal investigator 1 Boehringer Ingelheim International GmbH $1,534.00 03/06/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780126
Principal investigator 1 Boehringer Ingelheim International GmbH $4,500.00 03/06/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780128
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780074
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780076
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780078
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780080
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220780082
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780130
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780132
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780134
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780136
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780138
Principal investigator 1 Eli Lilly and Company $92.75 02/25/2025 Non-covered Recipient Entity
RESEARCH ALLIANCE INC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187890616
Principal investigator 1 Eli Lilly and Company $15,170.00 02/11/2025 Non-covered Recipient Entity
RESEARCH ALLIANCE INC
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187889574
Principal investigator 1 ABBVIE INC. $1,589.90 02/06/2025 Non-covered Recipient Entity
CAROLINA DIGESTIVE DISEASES
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202446975
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780108
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780110
Principal investigator 1 Boehringer Ingelheim International GmbH $3.37 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780112
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780114
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780116
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780118
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780120
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 01/24/2025 Non-covered Recipient Entity
Carolina Digestive Diseases PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220780122